

Supplementary Table 1. Profile of age distribution, comorbidities and length of stay among all hospitalized adults during the study period.

	2020		2021		Total	
	n=764	%	n=1129	%	n=1893	%
<b>Age groups</b>						
18-45 years	404	52.88	450	39.86	854	45.11
46-60	189	24.74	358	31.71	547	28.90
>60	171	22.38	321	28.43	492	25.99
<b>Comorbidity</b>						
Hypertension	146	19.11	234	20.73	380	20.07
Diabetes	143	18.72	179	15.85	322	17.01
Hypothyroidism	29	3.80	68	6.02	97	5.12
Coronary artery disease	21	2.75	33	2.92	54	2.85
Other cardiac disorders (rheumatic heart disease, pericardial effusion, others)	17	2.23	17	1.51	34	1.80
Stroke	12	1.57	6	0.53	18	0.95
Other neurological disorders (seizure, Parkinson, myasthenia gravis, others)	18	2.36	27	2.39	45	2.38
Chronic respiratory diseases	18	2.35	37	3.27	55	2.90
Tuberculosis	16	2.09	11	0.97	27	1.43
Chronic kidney disease	15	1.96	11	0.97	26	1.37
Leukemia	8	1.05	16	1.42	24	1.27
Other malignancies (Carcinoma bladder, Carcinoma lung, Hodgkin's lymphoma, others)	17	2.23	13	1.15	30	1.58
Chronic liver disease	4	0.52	5	0.44	9	0.48
Miscellaneous (human immunodeficiency virus, hepatitis B, hepatitis C, others)	71	9.29	73	6.47	144	7.61
<b>Length of stay (days)*</b>						
< 1	36	4.76	34	3.04	70	3.73
1 - 7	238	31.44	513	45.84	751	40.03
8--14	313	41.35	426	38.07	739	39.39
15 -- 21	110	14.53	101	9.03	211	11.25
22 -- 28	37	4.89	26	2.32	63	3.36
> 28	23	3.04	19	1.70	42	2.24
<b>Number of co-morbidities in 1 person</b>						
0	432	56.54	674	59.70	1106	58.43
1	190	24.87	255	22.59	445	23.51
2	96	12.57	144	12.75	240	12.68
3	34	4.45	40	3.54	74	3.91
≥4	12	1.57	16	1.42	28	1.48

\*Length of stay was not available for 7 patients in 2020 and 10 patients in 2021, making n=757 & n=1119 during 2020 and 2021 respectively.

Supplementary Table 2. Comparison of published data from European countries, Iran and Japan of all hospitalized cases.

Country [Reference Number]		Germany [10]	United Kingdom [11]	Spain (Reus) [5]	Japan [8]	Babol, Iran [9]	Italy [6]	Current Study, India
Cases	First wave	174	983	204	3833	728	132	764
	Second wave	331	1383	264	1361	1594	171	1129
Death	First wave	27	292	-	279	170	29	147
	Second wave	54	342	-	16	127	32	273
Case fatality rate	First wave	18%	29.70%	24%	7.30%	23.40%	21.9%	19.20%
	Second wave	20%	24.70%	13.20%	1.20%	8.00%	18.7%	24.18%
Age	First wave	59 (46,71)	70.3 (53.9 - 83.2)	67 ± 18	56 (40, 71)	56.84±18.29	74	45.4
	Second wave	58 (42,73)	67.5 (52.3 - 82.4)	58 ± 26	37 (25, 43)	53.60±23.05	72	49.8
Male	First wave	63%	53%	55.90%	59.50%	56.90%	65.15%	53.01%
	Second wave	53%	53%	54.50%	58.60%	48.10%	66.08%	58.10%
Length of stay (in days)	First wave	14 (8,34)	7.6 (3.4 - 14)	14 ± 19	-	-	16.3	10.45
	Second wave	11 (5,19)	6.6 (3.2 - 11.9)	22 ± 25	-	-	11.7	8.67
Duration from onset of symptoms to hospitalization	First wave	-	4.9 (1 -10)	-	7 (4, 10)	-	-	-
	Second wave	-	4.7 (2 - 8)	-	4 (2,0)	-	-	-

Comorbidities (%) in all hospitalized cases								
<b>Cardiovascular disease</b>	First wave	47	26.4	52.9	5.9	21.6	50.7	4.97
	Second wave	50	31.5	54.5	1.3	17.8	94.1	4.42
<b>Diabetes mellitus</b>	First wave	20	24	27.4	6.1	21.2	-	18.72
	Second wave	21	26	24.2	1.3	22.8	-	15.85
<b>Hypertension</b>	First wave	-	48	-	4	6.3	-	19.11
	Second wave	-	45	-	1.1	17.3	-	20.73
<b>Chronic kidney disease</b>	First wave	21	20	15.6	1.5	3.6	-	1.96
	Second wave	14	15	12.9	0.6	5.5	-	0.97
<b>Respiratory diseases</b>	First wave	15	54	15.2	14.2	4.9	21.2	2.35
	Second wave	12	49.7	17.8	7.9	3.1	17.5	3.27
<b>Malignancy</b>	First wave	5	12	14.2	3.7	1.1	15.9	3.27
	Second wave	10	12	16.3	1.5	2.6	17.5	2.56